Phage-mediated bioluminescent detection of Yersinia pestis

噬菌体介导的鼠疫耶尔森菌生物发光检测

基本信息

  • 批准号:
    8238277
  • 负责人:
  • 金额:
    $ 30.93万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2009
  • 资助国家:
    美国
  • 起止时间:
    2009-03-12 至 2014-02-28
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Yersinia pestis is designated by the Centers for Disease Control (CDC) and NIAID as a Category A bacterial pathogen. Y. pestis is the etiological agent of the plague (Black Death), a transmissible disease that has been responsible for millions of deaths throughout the course of history. Although the natural occurrence of this disease is now relatively rare, the possibility of terrorist groups using Y. pestis as a bioweapon is real. Because of the disease's inherent communicability, rapid clinical course, and high mortality, it is critical that an outbreak be detected quickly. Therefore methodologies that provide rapid detection and diagnosis are essential to ensure immediate implementation of public health measures and activation of crisis management. The long-term goal and commercial application of this proposal is to develop a plague diagnostic detection kit. The Phase I research successfully completed the proof of principle study and generated a recombinant luxAB ('light')-tagged reporter phage for the detection of Y. pestis. Y. pestis specific phage are currently used by the CDC and the World Health Organization (WHO) as a diagnostic standard for the confirmed identification of Y. pestis; however, the phage lysis assays are laboratory based and require 2 to 3 days to complete. In contrast, the technology described in this proposal does not require sample processing, a laboratory environment, or extensive incubation periods. The Phase I results demonstrated that the luxAB reporter phage rapidly conferred a bioluminescent signal response to an attenuated Y. pestis strain and displayed potential as a plague diagnostic. The Phase II research will build upon the Phase I foundation with the goal of generating a plague diagnostic kit. The Phase II research will: (i) increase the specificity and sensitivity of the reporter phage for Y. pestis (Aim 1); (ii) demonstrate the utility of the reporter phage against a library of wild-type Y. pestis strains (Aim 2); (iii) analyze the specificity of the reporter phage for Y. pestis using a panel of pathogenic non-pestis Yersinia species (Aim 3), and (iv) analyze and optimize the ability of the detection system to function directly with clinical specimens (Aim 4). Collectively, this research will provide the foundation for a plague diagnostic kit using novel 'light producing' reporter phage that rapidly, sensitively, and specifically confer a bioluminescent phenotype to Y. pestis. The vision of the product is that it can be used as a diagnostic for suspected plague-infected patients with cultivated isolates or directly with infected clinical specimens in a laboratory setting or as a portable camera-based assay. The long-term goal of our research is to develop a reporter phage-based multiplex assay for the identification of different bacterial priority A pathogens. PUBLIC HEALTH RELEVANCE: This proposal is significant because it will generate a rapid plague diagnostic test kit. A rapid diagnostic test kit is essential in order to specifically diagnose the disease, prevent the spread of the disease, and to save lives.
描述(由申请人提供):鼠疫耶尔森菌被疾病控制中心(CDC)和NIAID指定为A类细菌病原体。Y.鼠疫是鼠疫(黑死病)的病原体,黑死病是一种传染病,在整个历史过程中造成数百万人死亡。尽管这种疾病的自然发生现在相对罕见,但恐怖组织利用Y.鼠疫作为生物武器是真实的。由于该疾病固有的传染性、快速的临床病程和高死亡率,迅速发现疫情至关重要。因此,提供快速检测和诊断的方法对于确保立即执行公共卫生措施和启动危机管理至关重要。 本项目的长期目标和商业应用是开发鼠疫诊断检测试剂盒。第一阶段研究成功完成了原理研究的证明,并产生了一个重组的luxAB(“轻”)标记的报告噬菌体用于检测Y。鼠疫Y.鼠疫特异性噬菌体目前被CDC和世界卫生组织(WHO)用作确认鉴定Y.然而,噬菌体裂解测定是基于实验室的,需要2至3天才能完成。相比之下,本提案中描述的技术不需要样品处理、实验室环境或长时间的孵育期。I期结果表明,luxAB报告噬菌体迅速赋予对减毒Y的生物发光信号响应。鼠疫菌株,并显示出作为鼠疫诊断的潜力。第二阶段的研究将建立在第一阶段的基础上,目标是生产鼠疫诊断试剂盒。II期研究将:(i)提高报告噬菌体对Y的特异性和敏感性。鼠疫菌(目标1);(ii)证明了报告噬菌体对野生型Y.鼠疫菌株(Aim 2);使用一组致病性非鼠疫耶尔森氏菌物种检测鼠疫(目标3),以及(iv)分析和优化检测系统直接与临床标本一起起作用的能力(目标4)。 总的来说,这项研究将为鼠疫诊断试剂盒提供基础,该试剂盒使用新的“发光”报告噬菌体,快速,灵敏,特异性地赋予Y。鼠疫该产品的愿景是,它可以作为一种诊断与培养的分离株或直接与感染的临床标本在实验室设置或作为一个便携式相机为基础的测定疑似梅毒感染的患者。我们的研究的长期目标是开发一种基于报告噬菌体的多重检测方法,用于鉴定不同的细菌A级病原体。 公共卫生相关性:该提案意义重大,因为它将产生一种快速鼠疫诊断试剂盒。快速诊断检测试剂盒是必不可少的,以具体诊断疾病,防止疾病的传播,并挽救生命。

项目成果

期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(1)
Phage-based platforms for the clinical detection of human bacterial pathogens.
  • DOI:
    10.4161/bact.19274
  • 发表时间:
    2012-04-01
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Schofield DA;Sharp NJ;Westwater C
  • 通讯作者:
    Westwater C
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

DAVID A SCHOFIELD其他文献

DAVID A SCHOFIELD的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('DAVID A SCHOFIELD', 18)}}的其他基金

Phage-accelerated test system for ID/AST of urinary tract infections
尿路感染 ID/AST 噬菌体加速检测系统
  • 批准号:
    9407512
  • 财政年份:
    2017
  • 资助金额:
    $ 30.93万
  • 项目类别:
Bioluminescent reporter phage for the diagnostic detection of shigellosis
用于志贺氏菌病诊断检测的生物发光报告噬菌体
  • 批准号:
    8839507
  • 财政年份:
    2014
  • 资助金额:
    $ 30.93万
  • 项目类别:
Detection of Biodefense Pathogens Using Phage Diagnostics
使用噬菌体诊断检测生物防御病原体
  • 批准号:
    8694755
  • 财政年份:
    2014
  • 资助金额:
    $ 30.93万
  • 项目类别:
Detection of Biodefense Pathogens Using Phage Diagnostics
使用噬菌体诊断检测生物防御病原体
  • 批准号:
    8819100
  • 财政年份:
    2014
  • 资助金额:
    $ 30.93万
  • 项目类别:
Bioluminescent reporter phage for the diagnostic detection of shigellosis
用于志贺氏菌病诊断检测的生物发光报告噬菌体
  • 批准号:
    8300507
  • 财政年份:
    2012
  • 资助金额:
    $ 30.93万
  • 项目类别:
Bioluminescent reporter phage for the diagnostic detection of shigellosis
用于志贺氏菌病诊断检测的生物发光报告噬菌体
  • 批准号:
    8475556
  • 财政年份:
    2012
  • 资助金额:
    $ 30.93万
  • 项目类别:
Phage-mediated bioluminescent detection of Yersinia pestis.
噬菌体介导的鼠疫耶尔森菌生物发光检测。
  • 批准号:
    7664751
  • 财政年份:
    2009
  • 资助金额:
    $ 30.93万
  • 项目类别:
Phage-mediated bioluminescent detection of Yersinia pestis
噬菌体介导的鼠疫耶尔森菌生物发光检测
  • 批准号:
    8123772
  • 财政年份:
    2009
  • 资助金额:
    $ 30.93万
  • 项目类别:
Identifying targets for diagnosing oral candidiasis
确定诊断口腔念珠菌病的目标
  • 批准号:
    6993117
  • 财政年份:
    2005
  • 资助金额:
    $ 30.93万
  • 项目类别:

相似海外基金

A platform for rapidly generating live attenuated enterovirus vaccines
快速生成减毒肠道病毒活疫苗的平台
  • 批准号:
    24K02286
  • 财政年份:
    2024
  • 资助金额:
    $ 30.93万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
I-Corps: Translation potential of an efficient method to generate live-attenuated and replication-defective DNA viruses for vaccine development
I-Corps:一种有效方法的转化潜力,可生成用于疫苗开发的减毒活病毒和复制缺陷型 DNA 病毒
  • 批准号:
    2420924
  • 财政年份:
    2024
  • 资助金额:
    $ 30.93万
  • 项目类别:
    Standard Grant
Developing a robust native extracellular matrix to improve islet function with attenuated immunogenicity for transplantation
开发强大的天然细胞外基质,以改善胰岛功能,并减弱移植的免疫原性
  • 批准号:
    10596047
  • 财政年份:
    2023
  • 资助金额:
    $ 30.93万
  • 项目类别:
Live attenuated non-transmissible (LANT) Klebsiella pneumoniae vaccines
肺炎克雷伯氏菌减毒非传染性 (LANT) 活疫苗
  • 批准号:
    10742028
  • 财政年份:
    2023
  • 资助金额:
    $ 30.93万
  • 项目类别:
Protecting Pigs From Enzootic Pneumonia: Rational Design Of Safe Attenuated Vaccines.
保护猪免受地方性肺炎:安全减毒疫苗的合理设计。
  • 批准号:
    BB/X017540/1
  • 财政年份:
    2023
  • 资助金额:
    $ 30.93万
  • 项目类别:
    Research Grant
A “Goldilocks” live attenuated poultry vaccine for Infectious Coryza
用于传染性鼻炎的“Goldilocks”家禽减毒活疫苗
  • 批准号:
    LP210301365
  • 财政年份:
    2023
  • 资助金额:
    $ 30.93万
  • 项目类别:
    Linkage Projects
A novel live-attenuated Zika vaccine with a modified 5'UTR
一种带有改良 5UTR 的新型寨卡减毒活疫苗
  • 批准号:
    10730832
  • 财政年份:
    2023
  • 资助金额:
    $ 30.93万
  • 项目类别:
Combating melanoma with an attenuated bacterial therapeutic
用减毒细菌疗法对抗黑色素瘤
  • 批准号:
    10659841
  • 财政年份:
    2023
  • 资助金额:
    $ 30.93万
  • 项目类别:
Investigating Host and Viral Factors for Improved Design of Future Live Attenuated Vaccines for IBV
研究宿主和病毒因素以改进未来 IBV 减毒活疫苗的设计
  • 批准号:
    BB/V016067/1
  • 财政年份:
    2022
  • 资助金额:
    $ 30.93万
  • 项目类别:
    Research Grant
L2M NSERC-Bioengineering attenuated Sclerotinia sclerotiorum strains as bioherbicide for cereal production and lawn management
L2M NSERC-生物工程减毒核盘菌菌株作为谷物生产和草坪管理的生物除草剂
  • 批准号:
    576545-2022
  • 财政年份:
    2022
  • 资助金额:
    $ 30.93万
  • 项目类别:
    Idea to Innovation
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了